Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide.
Business Model:
Revenue: $25M
Employees: 51-200
Address: 115 South Union Street
City: Alexandria
State: VA
Zip: 22314
Country: US
Oxford Finance LLC delivers flexible financial solutions to healthcare and life sciences companies worldwide. Our capital provides clients with the fuel needed for innovation and growth.
Contact Phone:
+17035194900
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2014 | Asensus Surgical | Post-IPO Debt | 25M |
8/2015 | Ocera Therapeutics | Post-IPO Debt | 20M |
7/2014 | Cerus | Post-IPO Debt | 30M |
11/2015 | Continuum Healthcare | Debt Financing | 13.9M |
3/2011 | NeoVista | Debt Financing | 20M |
10/2019 | Equillium | Post-IPO Debt | 20M |
9/2020 | Vedanta Biosciences | Debt Financing | 15M |
10/2013 | Monteris Medical | Debt Financing | 5M |
12/2020 | RxSight | Debt Financing | 60M |
10/2012 | Entellus Medical | Debt Financing | 17M |
8/2014 | diaDexus | Post-IPO Debt | 15M |
9/2020 | Selecta Biosciences | Post-IPO Debt | 35M |
6/2022 | Antheia | Debt Financing | 0 |
12/2013 | Apollo Endosurgery | Debt Financing | 50M |
7/2015 | AlterG | Debt Financing | 15M |
7/2010 | Tethys BioScience | Debt Financing | 10M |
6/2012 | Avanir Pharmaceuticals | Post-IPO Debt | 30M |
11/2015 | Zyga Technology | Debt Financing | 15M |
11/2022 | Pearl Street | Debt Financing | 115M |
8/2013 | PrimeSource Healthcare Systems | Debt Financing | 5.5M |
10/2013 | Monteris Medical | Venture Round | 0 |
10/2022 | ALX Oncology | Post-IPO Debt | 100M |
1/2017 | Eiger BioPharmaceuticals | Post-IPO Debt | 25M |
7/2021 | 4D Pharma | Post-IPO Debt | 29.9M |
3/2016 | Superior Biologics | Debt Financing | 50M |
6/2016 | Regulus Therapeutics | Post-IPO Debt | 30M |
12/2013 | Amicus Therapeutics | Post-IPO Debt | 10M |
3/2019 | Evolus | Post-IPO Debt | 100M |
4/2014 | Larimar Therapeutics | Debt Financing | 20M |
2/2020 | Syros Pharmaceuticals | Debt Financing | 60M |
2/2019 | Continuing Healthcare Solutions | Debt Financing | 43.3M |
4/2017 | Cerapedics | Debt Financing | 20M |
5/2017 | Castle Biosciences | Debt Financing | 20M |
6/2019 | AcelRx Pharmaceuticals | Post-IPO Debt | 25M |
1/2015 | Minerva Neuroscience | Post-IPO Debt | 15M |
1/2022 | Choice Health at Home | Debt Financing | 0 |
5/2013 | CardioFocus | Debt Financing | 11M |
7/2010 | Zogenix | Debt Financing | 35M |
11/2017 | Puma Biotechnology | Post-IPO Equity | 100M |
5/2016 | ADMA Biologics | Post-IPO Debt | 4M |
8/2017 | AirXpanders | Post-IPO Debt | 15M |
10/2020 | SpendMend | Debt Financing | 55M |
12/2020 | Nature’s Fynd | Debt Financing | 45M |
6/2015 | ADMA Biologics | Post-IPO Debt | 21M |
4/2007 | Argos Therapeutics | Debt Financing | 5M |
9/2019 | Codex DNA | Series A | 25M |
7/2016 | Senseonics | Post-IPO Debt | 30M |
11/2017 | VitalConnect | Debt Financing | 20M |
2/2012 | Horizon Pharma | Post-IPO Debt | 60M |
4/2015 | Celula | Debt Financing | 10M |
9/2013 | Singulex, Inc. | Debt Financing | 40M |
7/2021 | Impel NeuroPharma | Debt Financing | 50M |
2/2022 | Centogene | Post-IPO Debt | 0 |
1/2017 | ConforMIS | Post-IPO Debt | 50M |
2/2011 | Intuity Medical | Venture Round | 20M |
3/2020 | Epic Healthcare Staffing | Debt Financing | 104.3M |
11/2021 | Viracta Therapeutics | Post-IPO Debt | 0 |
5/2021 | Kala Pharmaceuticals | Post-IPO Debt | 125M |
9/2020 | Enable Injections | Debt Financing | 25M |
8/2019 | MolecuLight | Debt Financing | 7.5M |
4/2014 | Conventus Orthopaedics | Debt Financing | 10M |
12/2013 | CymaBay Therapeutics | Debt Financing | 5M |
4/2017 | Reata Pharmaceuticals | Post-IPO Debt | 35M |
9/2010 | SuperDimension | Debt | 15M |
7/2014 | Cardiff Oncology | Post-IPO Debt | 15M |
6/2014 | Tobira Therapeutics | Debt Financing | 15M |
3/2018 | Xeris Pharmaceuticals | Debt Financing | 45M |
3/2011 | AirXpanders | Series C | 3M |
11/2021 | Platelet BioGenesis | Series B | 75.5M |
10/2007 | Tengion | Series C | 33M |
3/2022 | Verastem Oncology | Post-IPO Debt | 0 |
10/2022 | Verona Pharma | Post-IPO Debt | 150M |
5/2012 | Pacira Pharmaceuticals | Post-IPO Debt | 27.5M |
1/2014 | Auspex Pharmaceuticals | Debt Financing | 15M |
8/2016 | CVRx | Debt Financing | 20M |
9/2014 | Trevena | Post-IPO Debt | 35M |
12/2015 | Aratana Therapeutics | Post-IPO Debt | 40M |
8/2014 | Tarsa Therapeutics | Debt Financing | 10M |
5/2014 | Ceterix Orthopaedics | Debt Financing | - |
10/2009 | Zogenix | Series B | 36M |
9/2014 | Pulmonx | Debt Financing | 20M |
5/2015 | Edgemont Pharmaceuticals | Debt Financing | 5M |
9/2020 | Collage Rehabilitation Partners | Debt Financing | - |
9/2019 | Xeris Pharmaceuticals | Post-IPO Debt | 85M |
4/2019 | Summit Healthcare REIT | Debt Financing | 96M |
10/2019 | LogicBio Therapeutics | Post-IPO Debt | 20M |
9/2012 | CareDx | Debt Financing | 15M |
5/2022 | Silk Road Medical | Post-IPO Debt | 250M |
8/2016 | Bi02 Medical | Debt Financing | 3M |
1/2017 | Oxford BioTherapeutics | Debt Financing | 10M |
2/2012 | Ceptaris Therapeutics | Debt Financing | 15M |
8/2014 | HTG Molecular Diagnostics | Debt Financing | 16M |
1/2015 | InterValve | Debt Financing | 3M |
8/2011 | Keystone Dental | Debt Financing | 20M |
8/2019 | ObsEva | Post-IPO Debt | 75M |
12/2016 | Strongbridge Biopharma | Post-IPO Debt | 40M |
3/2014 | Omeros | Post-IPO Debt | 32M |
6/2014 | Intellicyt | Debt Financing | 4M |
11/2022 | Renibus Therapeutics | Debt Financing | 10M |
5/2016 | Omeros | Post-IPO Debt | 20M |
1/2016 | Omeros | Post-IPO Debt | 70M |
1/2021 | Immunocore | Debt Financing | 100M |
9/2007 | CASI Pharmaceuticals | Post-IPO Debt | 20M |
12/2016 | Veran Medical Technologies | Venture Round | 31M |
5/2015 | Labcyte | Debt Financing | 17M |
11/2015 | Venus Concept | Debt Financing | 20M |
6/2016 | Monteris Medical | Debt Financing | 10M |
6/2014 | Durect | Post-IPO Equity | 20M |
1/2016 | Bi02 Medical | Debt Financing | 5M |
2/2020 | Genapsys | Debt Financing | 75M |
4/2015 | Inhibrx | Debt Financing | 20M |
4/2012 | NanoString Technologies | Debt Financing | 15M |
4/2021 | Mainstay Medical | Debt | 50M |
11/2018 | Nevakar | Debt Financing | 30M |
7/2012 | LENSAR, Inc. | Debt Financing | 10M |
7/2013 | Continuum Healthcare | Debt Financing | 11.5M |
12/2013 | Halozyme Therapeutics | Post-IPO Debt | 30M |
4/2018 | Cardiac Dimensions | Series B | 39M |
4/2014 | Senseonics | Debt Financing | 10M |
1/2014 | Halozyme Therapeutics | Post-IPO Debt | 20M |
12/2020 | Greenbrook TMS | Post-IPO Debt | 30M |
11/2007 | BioVex | Series E | 35M |
11/2021 | Kezar Life Sciences | Post-IPO Debt | 50M |
3/2011 | SynergEyes | Venture Round | 5M |
6/2014 | Relypsa | Post-IPO Debt | 35M |
6/2022 | SeLux Diagnostics | Debt Financing | 0 |
2/2009 | Pearl Therapeutics | Debt Financing | 8M |
12/2015 | MDRejuvena | Debt Financing | 3M |
12/2013 | Acura Pharmaceuticals | Post-IPO Debt | 10M |
11/2011 | Avantis Medical Systems | Debt Financing | 3M |
7/2010 | Zogenix | Venture Round | 0 |
1/2022 | Sierra Oncology | Post-IPO Debt | 125M |
4/2016 | Nuvectra | Debt Financing | 45M |
6/2016 | Ignyta | Post-IPO Debt | 42M |
5/2019 | RefleXion Medical | Debt Financing | 60M |
10/2020 | Scholar Rock | Post-IPO Debt | 50M |
7/2018 | QuVa Pharma | Debt Financing | 41M |
3/2014 | Navidea Biopharmaceuticals | Post-IPO Debt | 30M |
11/2018 | Karius | Debt Financing | 25M |
11/2014 | Lexicon Pharmaceuticals | Equity | 150M |
4/2015 | ReShape Lifesciences | Post-IPO Debt | 12M |
7/2013 | Plus Therapeutics | Post-IPO Debt | 27M |
1/2019 | AliveCor | Debt Financing | 20M |
1/2013 | Agile Therapeutics | Debt Financing | 15M |
1/2014 | Proteus Digital Health | Debt Financing | 31.6M |
4/2014 | RF Surgical Systems | Venture Round | 15M |
6/2022 | Antheia | Debt Financing | 0 |
6/2022 | SeLux Diagnostics | Debt Financing | 0 |
5/2022 | Silk Road Medical | Post-IPO Debt | 0 |
3/2022 | Verastem Oncology | Post-IPO Debt | 0 |
3/2022 | Lexicon Pharmaceuticals | Post-IPO Debt | 0 |
2/2022 | Centogene | Post-IPO Debt | 0 |
1/2022 | Sierra Oncology | Post-IPO Debt | 0 |
1/2022 | Choice Health at Home | Debt Financing | 0 |
11/2021 | Kezar Life Sciences | Post-IPO Debt | 0 |
11/2021 | Viracta Therapeutics | Post-IPO Debt | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|